Pharmaceuticals company Caplin Point Laboratories announced Q1FY26 results Gross Margin for Q1FY26 is 61.7% vs 59.6% in Q1FY25 aided by new product launches across existing and new markets. EBITDA Margin for Q1FY26 is at 37.7% vs 35.7% in Q1FY25. Basic EPS increased by 23.1% to Rs 20.10 in Q1FY26 compared to Rs 16.32 in Q1FY25. Cash Flow from Operations in Q1FY26 is Rs 118 crore vs Rs 96 crore in Q1FY25. Free Cash Flow is Rs 53 crore (after Capex investment of Rs 65 crore) in Q1FY26 as compared to Rs 59 crore (after capex investment of Rs 37 crore) in Q1FY25. Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1FY26 is in the range of 79% and 21% respectively. CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1FY26 in the range of 85% and 15% respectively. As of 30th June 2025, Inventories are at Rs 324 crore - 56% Stock at the warehouses, close to the customer; In Transit 13%; 31% in India. Receivables are at 114 days. As of 30th June 2025, Free Cash reserves are at Rs 1,237 crore and Total Liquid Assets at Rs 2,207 crore. C.C. Paarthipan, Chairman, said: "We’re putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows." Result PDF